PRINCETON, NJ, Feb. 11, 2015 – Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
Destum Partners Acts as Transaction Advisor to WILEX in Licensing Deal for MESUPRON® in China with Link Health Group
MUNICH, GERMANY / GUANGZHOU, CHINA, March 28, 2014 – WILEX AG today announced that it has entered into a licensing and development partnership for MESUPRON® with Link Health Co., Guangzhou, China. Link Health will receive the exclusive licensing rights for the development and marketing of MESUPRON® in China, Hong Kong, Taiwan and Macao. The US-based consulting firm Destum Partners Inc., Charlotte, NC, USA, acted as transaction advisor to WILEX for this transaction.
Destum Partners Represents BMG Pharma S.r.l. in Identifying and Securing Vestiq Pharmaceuticals as Company’s First U.S. Distributor
MORRISVILLE, NC, February 5, 2013 – Vestiq Pharmaceuticals, Inc. today announced that it has taken the rights for distribution of GelX Oral Gel from BMG Pharma S.r.l. GelX is an oral solution for the treatment and maintenance of Oral Mucositis most commonly caused by chemotherapy, radiotherapy, and other related pharmacological therapies.